Does A Link Exist Between Endometriosis & IBS? A naturopath explains...

A link has been identified between both endometriosis and irritable bowel syndrome (IBS).

Case features are similar between the two conditions, with Seaman et al. 2008 finding that women with endometriosis are 3.5x more likely to be diagnosed with IBS.

Please note that not every woman with endometriosis will have IBS (or vice versa), however the connection is worth considering.

My Clinical Experience with Endometriosis & IBS

Clinically speaking, I have noticed that almost (if not every) woman I see in clinic with endometriosis, also presents with some sort of digestive issue. It may be IBS or it may simply be written off as a bit of 'funny tummy'.

Funnily enough the term 'endo belly' has been coined for this very phenomenon! Demonstrating that digestive issues are indeed a predominant issue experienced by women with endometriosis.

How Can Naturopathy Help You?

As discussed below, it is evident that a breakdown in the integrity of the gut microbiota is implemented in both IBS and endometriosis. Therefore, it means that the health of your gut can directly impact those with IBS and/or endometriosis.

When working with either IBS or endometriosis (or both!) we need to figure out the exact cause behind your symptoms. Common factors contributing to poor gut health include: diet, lifestyle, stress, history of antibiotic use, nutrient deficiencies, hormonal imbalance, parasite infection, bacterial or overgrowth (e.g. candida), low stomach acid plus many more!

Naturopathic treatment protocols are centred upon addressing the root cause of your health concerns, then working to correct these issues using natural herbs, nutrients, diet changes and lifestyle modifications.

Many changes can be made for IBS and endometriosis severity; using naturopathic solutions that are tailored to suit your individual case presentation & needs.

What is Endometriosis?

Endometriosis affects 5-10% of reproductive aged women (2), with diagnosis being made via laparoscopy. (3) Ultrasound can aid with identification of lesions.(3) Endometriosis can result in dyspareunia, dysmenorrhea, low back pain and infertility (3)

Many women present with no symptoms, however the (2) main symptoms observed are (3):

  1. Pain occurring in the place of endometrial tissue growth – often the pelvis – with pain usually peaking in a cyclical nature with the menstrual cycle. Women often experience painful intercourse too(3)

  2. Sub-fertility or infertility – oftentimes this is when a diagnosis is made(3)

Current Medical Management of Endometriosis

Pharmacotherapy is centred upon pain management, (4,5) with most treatments focusing on the suppression of ovarian function.

These treatments are symptomatic and are not curative.(4,5) Combined oral contraceptives (OC) and progestins are often used for pain relief. (8,9) Gonadotropin-releasing agents are utilised when aforementioned treatment is ineffective, not tolerated or ineffective. (4,5) If dysmenorrhea (pain) is the main clinical complaint, with peritoneal implants or ovarian endometriomas <5cm; OC’s are recommended.(5) For severe deep dyspareunia & infiltrating lesions; progestogens are often preferred.(5)

What is Irritable Bowel Syndrome (IBS)?

• Rome Criteria IV is gold standard for diagnosis(15)

Recurrent abdominal pain, on average, at least 1 day/week in last 3 months, associated with two or more of the following criteria:

- Related to defecation

- Association with a change in frequency to stool

- Associated with a change in form (appearance) of stool.

• Pathophysiology not yet completely understood (16)

• 80% of those affected are female (17)

Medical Management of IBS

• Pharmaceutical management of IBS symptoms differs from patient to patient & each presentation must be evaluated by it’s own merit

Current pharmaceutical interventions include: tricyclic antidepressants and chloride channel agonists/antagonists(18)

• 5-HT3 antagonists, 5-HT4 agonists and GCC agonists, antispasmodics, and alosetron were suggestive for the treatment of IBS (19). However, concerns for bias with GCC have been noted, meaning it should be used with caution.

• IBS treatments also note a high placebo effect response; ranging from 30-80%(20)

The IBS & Endometriosis Link

• Both IBS & endometriosis share some similar clinical features, namely chronic low-grade inflammation as the basis for disease chronicity(21,22,23)

• Key inflammatory markers present in both conditions include: mast cell activation, neuronal inflammation, dysbiosis and impaired intestinal permeability(21)

Pelvic pain is often present in both conditions

Mast Cells in IBS & Endometriosis

• Mast cells contain many nociceptive substances; when broken these are released into interstitial fluid whereby they exert an effect

• Mast cells have been found to be high in both IBS (24,25) and endometriosis(26,27)

• Perpetuating chronic inflammation in both conditions

Neurogenic Inflammation (NI) in IBS & Endometriosis

• NI is largely responsible for pelvic pain(27)

• Calcitonin & substance-P play significant role in (NI); promoting the breakdown of mast cells(28,29,30)

• The presence of NI give rise to persistent low-grade chronic inflammation in both IBS & endometriosis(21)

Dysbiosis: IBS

• Modification to the microbiota has been implicated in many pathological conditions(21)

• IBS patients present with lower concentrations of Bacterioidetes and an increase of Fermicutes and Actinobacteria; when compared to a ’healthy’ control group(31,32)

• The severity of gastrointestinal symptoms is often relative to the level of dysbiosis (33)

Dysbiosis: Endometriosis

• The endometrial composition in animal models have shown a decreased concentration of Lactobacilli, with an increase in Gram negative bacteria, in comparison to controls(21)

• Intestinal inflammation is often higher in those with endometriosis (34,35)

Intestinal Permeability in IBS & Endometriosis

• The integrity of intestinal junctions are dependent on substances found within the gut lining

• Some medications (NSAID’s) have a negative effect on the intestinal mucosa(36,37)a

• This can create permeability – resulting in IBS(38)

• Dysbiosis is associated with intestinal permeability, resulting in the translocation of LPS-endotoxins which have been implicated in endometriosis(39)

• The connection between intestinal disruption and endometriosis is significant because it opens up windows in regards to how we view & treat IBS and endometriosis

A note on NSAID’s…

• NSAID’s have been directly linked to intestinal permeability (36)

• This can result in the translocation of bacteria(40)

• Triggering an inflammatory cascade which may play a role in many diseases including IBS and endometriosis(41,42)

• NSAID’s should be prescribed judiciously given their potential implications in disease

A word on hormonal influence…

Dysmenorrhea (painful periods) has been associated with IBS(1,43)

• It has also been noted that IBS symptoms improve post-menopause – further indicating a hormonal influence(44)

• Interestingly, GnRH intervention improves symptoms of both IBS and endometriosis(45, 46, 47,48)

• Demonstrating that altering hormonal function (in this case ovulation) has positive effects for a seemingly unrelated condition such as IBS.


  • Treatment of either/or IBS and/or endometriosis should take into consideration the aforementioned information

  • A well established link between the two exists in the literature

  • Further research into causal relationships needs to be conducted

  • This will allow greater understanding of the connection between the conditions & future treatment options

  • Current naturopathic treatment options work to decipher the root cause of an individual's problems (e.g. menstrual pain or upset tummy) and correct these issues

Sydney Naturopath -Hornsby Naturopath - Online Naturopath

This article is authored by Emma Clegg who is a qualified naturopath located in Sydney, Australia.

Emma has a special interest in all areas of female heath, gastrointestinal health and allergies.

Appointments are available from her clinic in Hornsby. Online consultations are also available from anywhere in the world.

Book your appointment now via email: or phone: (02) 9476 6888 or 0435 609 957.


  1. Seaman HE, Ballard KD, Wright JT, de Vries CS. Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study--part 2. BJOG. 2008;115:1392-6.

  2. Wellbery C. Diagnosis and treatment of endometriosis. Am Fam Physician [Internet]. [cited Nov 12] 1999;60:1753–62.

  3. The Royal Australian and New Zealand College of Obstrtricians and Gynaecologists (RANZCOG), Women’s Health – Endometriosis. Link: resources/endometriosis

  4. Ferrero S Current and emerging treatment options for endometriosis. Expert Opin Pharmacother . 2018 [cited Nov12th];19(10):1109-1125. View: doi: 10.1080/14656566.2018.1494154. Epub 2018 Jul 5.

  5. Vercellini P et al. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol . 2018 [cited Nov 12th];51:68-91. doi: 10.1016/j.bpobgyn.2018.01.015.

  6. Arcoverde FVL et al. Surgery for Endometriosis Improves Major Domains of Quality of Life: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2019 [viewed 12 Nov] ;26(2):266-278. doi: 10.1016/j.jmig.2018.09.774.

  7. Singh S et al. Surgical Outcomes in Patients With Endometriosis: A Systematic Review J Obstet Gynaecol Can. 2020 [Viewed 12th Nov];42(7):881-888.e11. doi: 10.1016/j.jogc.2019.08.004.

  8. Leonardi M et al .When to Do Surgery and When Not to Do Surgery for Endometriosis: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020 [viewed 12 Nov];27(2):390-407.e3.

  9. ChaichianS et al. Comparing the Efficacy of Surgery and Medical Therapy for Pain Management in Endometriosis: A Systematic Review and Meta-analysis. Pain Physician . 2017 [cited Nov12] ;20(3):185-195.

  10. Vercellini P et al. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol . 2018 [cited Nov 12th];51:68-91. doi: 10.1016/j.bpobgyn.2018.01.015.

  11. Nisenblat V et al. Combination of the non-invasive tests for the diagnosis of endometriosis. Cochrane Database Syst Rev. 2016 [viewed Nov 12] 13;7(7):CD012281. doi: 10.1002/14651858.CD012281.

  12. Hirsch M et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG . 2016 [viewed 12 Nov];123(11):1761-8. doi: 10.1111/1471-0528.14055.

  13. Gupta D et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev . 2016 [Viewed 12th Nov] 20;4(4):CD012165. doi: 10.1002/14651858.CD012165.

  14. Creed J, Maggrah A, Reguly B, Harbottle A. Mitochondrial DNA deletions accurately detect endometriosis in symptomatic females of child-bearing age. Biomark Med. 2019 Mar;13(4):291-306. doi: 10.2217/bmm-2018-0419. Epub 2019 Jan 15. PMID: 30642196.

  15. Bai t et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J Gastroenterol Hepatol [Internet]. 2017 [cited 12th Nov]. 32(5):1018-1025. DOI: 10.1111/jgh.13642

  16. Radovanovic-Dinic B et al. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub . 2018 [cited Nov 12th];162(1):1-9. doi: 10.5507/bp.2017.057.

  17. Adriani A et al. Irritable bowel syndrome: the clinical approach. Panminerva Med . 2018 [cited Nov 12th]. 60(4):213-222. doi: 10.23736/S0031-0808.18.03541-3.

  18. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. PMID: 24944467; PMCID: PMC4051916.

  19. Chen M, Tang TC, Qin D, Yue L, Zheng H. Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review. J Gastrointestin Liver Dis. 2020 Jun 3;29(2):199-209. doi: 10.15403/jgld-817. PMID: 32530987.

  20. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-758 [PMID: 12738451 DOI: 10.1111/j.1572-0241.2003.07306.x]

  21. Viganò D, Zara F, Usai P. Irritable bowel syndrome and endometriosis: New insights for old diseases. Dig Liver Dis. 2018 Mar;50(3):213-219. doi: 10.1016/j.dld.2017.12.017. Epub 2017 Dec 27. PMID: 29396128.

  22. Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, et al. Inflammation in irritable bowel syndrome: myth or new treatment target? World J Gastroenterol 2016;22:2242–55, [50]

  23. Polak G, Barczynski ´ B, Bednarek W, Kwasniewski ´ W, Wertel I, DerewiankaPolak M, et al. Increased levels of proteins of the acute inflammatory phase in the peritoneal fluid of women with advanced stages of endometriosis. Ginekol Pol 2015;86:414–48,

  24. Xu XJ, Zhang YL, Liu L, Pan L, Yao SK. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Aliment Pharmacol Ther 2017;45:100–14,

  25. O’Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449–57,

  26. Kempuraj D, Papadopoulou N, Stanford EJ, Christodoulou S, Madhappan B, Sant GR, et al. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol 2004;52:267–75,

  27. Anaf V, Chapron C, El Nakadi I, De Moor V, Simonart T, Noël JC. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril 2006;86:1336–43,

  28. Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci 2012;15:1063–7,

  29. Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as cotransmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995;45:1–98,

  30. Andrews PV, Helme RD. Neurogenic plasma extravasation in response to mechanical, chemical and thermal stimuli. Clin Exp Neurol 1987;23:95–100.

  31. Escott KJ, Connor HE, Brain SD, Beattie DT. The involvement of calcitonin gene-related peptide (CGRP) and substance P in feline pial artery diameter responses evoked by capsaicin. Neuropeptides 1995;29:129–35,

  32. Jeffery IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EMM, et al. An irritable bowel syndrome subtype defined by speciesspecific alterations in faecal microbiota. Gut 2012;61:997–1006,

  33. Rajilic-Stojanovi ´ c´ M, Biagi E, Heilig HGHJ, Kajander K, Kekkonen RA, Tims S, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792–801,

  34. Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017;152:111–23,, e8.

  35. Laschke MW, Menger MD. The gut microbiota: a puppet master in the pathogenesis of endometriosis? Am J Obstet Gynecol 2016;215:68,, e1-68.e4.

  36. Bailey MT, Coe CL. Endometriosis is associated with an altered profile of intestinal microflora in female rhesus monkeys. Hum Reprod 2002;17:1704–8,

  37. Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009;44:23–9,

  38. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010;39:433–64,

  39. Piche T. Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil 2014;26:296–302,

  40. Khan KN, Kitajima M, Hiraki K, Yamaguchi N, Katamine S, Matsuyama T, et al. Escherichia coli contamination of menstrual blood and effect of bacterial endotoxin on endometriosis. Fertil Steril 2010;94:2860–3,

  41. Bein A, Zilbershtein A, Golosovsky M, Davidov D, Schwartz B. LPS induces hyper-permeability of intestinal epithelial cells. J Cell Physiol 2017;232:381–90,

  42. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev 2014;66:80–101,

  43. Altman G, Cain KC, Motzer S, Jarrett M, Burr R, Heitkemper M. Increased symptoms in female IBS patients with dysmenorrhea and PMS. Gastroenterol Nurs. 2006;29:4-11. 37.

  44. Crowell MD, Dubin NH, Robinson JC, et al. Functional bowel disorders in women with dysmenorrhea. Am J Gastroenterol. 1994;89:1973-7.

  45. Mayer EA, Naliboff B, Lee O, Munakata J, Chang L. Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther.

  46. Palomba S, Orio F Jr, Manguso F, et al. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. Fertil Steril. 2005;83:1012-20. 39.

  47. Franke HR, van de Weijer PH, Pennings TM, van der Mooren MJ. Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000;74:534-9. 40.

  48. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002;99:709-19.

45 views0 comments